Efficacy of Lidocaine Patch in Acute Musculoskeletal Pain in the Emergency Department (NCT03571737) | Clinical Trial Compass
CompletedPhase 3
Efficacy of Lidocaine Patch in Acute Musculoskeletal Pain in the Emergency Department
United States23 participantsStarted 2018-06-23
Plain-language summary
This study evaluates the addition of a lidocaine patch to ibuprofen in the treatment of acute musculoskeletal pains. Half of the participants will get only ibuprofen for their pain, while other half will receive lidocaine patch plus the ibuprofen. After addition of the pain medications, the participants will be followed for their pain scores and return visits.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Subject's age is greater than or equal to 18 years old
* Subject is able to speak English
* Subject has chief complaint of musculoskeletal pain lasting less than or equal to 7 days
* Subject's area of greatest pain isolated to one body part
* Subject does not have prior Emergency Department visits recorded on electronic medical records for the chief complaint
Exclusion Criteria:
* Subject's age is less than 18 years old
* Subject is pregnant or breastfeeding patients
* Subject cannot speak English
* Subject has multiple traumatic injuries or injury requiring consultation with the trauma service per study facility's guidelines
* Subject has cellulitis or infection overlying the injuries
* Subject has open wound overlying the injuries
* Subject's chief complaint is caused by penetrating injury
* Subject has absolute contraindications to study medications, including anaphylaxis to lidocaine or nonsteroidal antiinflammatory drugs, history of active GI bleeding or recent coronary artery bypass graft surgery precluding nonsteroidal antiinflammatory medications, severe hepatic disease (hepatitis, cirrhosis in current chart or prior history or elevation in liver function tests to clinically significant levels in past 6 months), severe kidney disease (Creatinine clearance less than 30 milliliters or history of chronic kidney disease stage 3 or worse), congestive heart failure.
* Subject has medication contraindications such as concurrent use of medications lis…